User login
Obese women taking oral contraceptives had a 30-fold increased odds for cerebral venous thrombosis (CVT), compared with normal-weight women, in an unmatched case-control study of 186 CVT cases and 6,134 controls.
The association between a body-mass index of 30 kg/m2 or higher and increased odds of CVT “appears to be fully attributable to a strongly increased risk in women who use oral contraceptives [OCs],” said Dr. Susanna M. Zuurbier of the Academic Medical Centre in Amsterdam, and her colleagues.
“Although the relative risks are increased substantially, the absolute risks of CVT are still small,” the researchers said. “Moreover, withholding oral contraceptives may lead to an increase in unintended pregnancies and thus the number of pregnancy-related thrombosis cases.”
After controlling for multiple variables, CVT was 2.63 times more likely to occur in obese individuals, compared with those of normal weight. When the findings were stratified by sex, a BMI greater than 30 kg/m2 had no significant impact on CVT in men, but the odds rose 3.5-fold in women, the investigators reported online March 14 in JAMA Neurology (JAMA Neurol. 2016 Mar 14. doi: 10.1001/jamaneurol.2016.000100).
On further analysis, overweight and obesity had a dose-dependent impact on the odds of CVT among women who used OCs. Adjusted odds ratios were 11.87 for those with BMIs ranging from 25 kg/m2 to 29 kg/m2, and 29.26 for those with BMIs of 30 kg/m2 or higher when compared against normal-weight women who did not use OCs. No association was found between obesity and CVT risk in women who did not use OCs, the researchers noted.
Patients with CVT were recruited in 2006-2014 from two medical centers, one in the Netherlands and the other in Switzerland. The controls were part of the Dutch Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA) study. Overall, patients with CVT were more likely to be younger than controls (median age 40 years vs. 48 years). They also were more likely than controls to be female (72% vs. 53%), users of oral contraceptives (73% vs. 24%) and have a history of cancer (9% vs. 4%).
The study was limited by several factors, including the small number of CVT cases, the lack of complete BMI data for the study population, and time difference in recruitment of cases and controls, the researchers noted, but they advised clinicians to keep the risk in mind when counseling obese women about OC use.
“Alternative methods of contraception that are not associated with thrombosis, such as an intrauterine device, might be offered to these women,” they wrote.
The study was funded by grants from the Netherlands Organisation for Scientific Research, the Dutch Thrombosis Society, the Remmert Adriaan Laan Foundation, and the Swiss Heart Foundation. Study coauthor Dr. Marcel Arnold disclosed receiving honoraria for giving lectures and serving on advisory boards for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Covidien.
“The discovery of increased rates of asymptomatic atherosclerosis in patients with VTE led to the systematic study of cardiovascular risk factors, such as obesity, in VTE,” but the possible association between obesity and CVT has not been explored, Dr. Chirantan Banerjee wrote in an accompanying editorial.
The current study results are “novel and in concordance with prior studies on obesity and OC use as risk factors for VTE,” Dr. Banerjee noted. The study’s strengths lie in the inclusion of appropriate subgroups, controls, and confounding variables. In addition to further research to validate the findings, “studies investigating the effect of inherited thrombophilia on the association between obesity and CVT would also be important because the current study did not have this data,” he noted. “Other potential confounders, such as obstructive sleep apnea and anemia, should be included in future studies.
In the meantime, “the authors correctly point out that despite the manifold increased relative risk, the absolute risk of CVT in obese women taking OCs still remains low and should not preclude OC use among them,” Dr. Banerjee said.
Dr. Banerjee is a member of the department of neurology at the Medical University of Charleston, S.C., and had no financial conflicts to disclose. These comments were taken from his editorial accompanying Dr. Zuurbier and colleagues’ report (JAMA Neurol. 2016 Mar 14. doi: 10.1001/jamaneurol.2015.5107).
“The discovery of increased rates of asymptomatic atherosclerosis in patients with VTE led to the systematic study of cardiovascular risk factors, such as obesity, in VTE,” but the possible association between obesity and CVT has not been explored, Dr. Chirantan Banerjee wrote in an accompanying editorial.
The current study results are “novel and in concordance with prior studies on obesity and OC use as risk factors for VTE,” Dr. Banerjee noted. The study’s strengths lie in the inclusion of appropriate subgroups, controls, and confounding variables. In addition to further research to validate the findings, “studies investigating the effect of inherited thrombophilia on the association between obesity and CVT would also be important because the current study did not have this data,” he noted. “Other potential confounders, such as obstructive sleep apnea and anemia, should be included in future studies.
In the meantime, “the authors correctly point out that despite the manifold increased relative risk, the absolute risk of CVT in obese women taking OCs still remains low and should not preclude OC use among them,” Dr. Banerjee said.
Dr. Banerjee is a member of the department of neurology at the Medical University of Charleston, S.C., and had no financial conflicts to disclose. These comments were taken from his editorial accompanying Dr. Zuurbier and colleagues’ report (JAMA Neurol. 2016 Mar 14. doi: 10.1001/jamaneurol.2015.5107).
“The discovery of increased rates of asymptomatic atherosclerosis in patients with VTE led to the systematic study of cardiovascular risk factors, such as obesity, in VTE,” but the possible association between obesity and CVT has not been explored, Dr. Chirantan Banerjee wrote in an accompanying editorial.
The current study results are “novel and in concordance with prior studies on obesity and OC use as risk factors for VTE,” Dr. Banerjee noted. The study’s strengths lie in the inclusion of appropriate subgroups, controls, and confounding variables. In addition to further research to validate the findings, “studies investigating the effect of inherited thrombophilia on the association between obesity and CVT would also be important because the current study did not have this data,” he noted. “Other potential confounders, such as obstructive sleep apnea and anemia, should be included in future studies.
In the meantime, “the authors correctly point out that despite the manifold increased relative risk, the absolute risk of CVT in obese women taking OCs still remains low and should not preclude OC use among them,” Dr. Banerjee said.
Dr. Banerjee is a member of the department of neurology at the Medical University of Charleston, S.C., and had no financial conflicts to disclose. These comments were taken from his editorial accompanying Dr. Zuurbier and colleagues’ report (JAMA Neurol. 2016 Mar 14. doi: 10.1001/jamaneurol.2015.5107).
Obese women taking oral contraceptives had a 30-fold increased odds for cerebral venous thrombosis (CVT), compared with normal-weight women, in an unmatched case-control study of 186 CVT cases and 6,134 controls.
The association between a body-mass index of 30 kg/m2 or higher and increased odds of CVT “appears to be fully attributable to a strongly increased risk in women who use oral contraceptives [OCs],” said Dr. Susanna M. Zuurbier of the Academic Medical Centre in Amsterdam, and her colleagues.
“Although the relative risks are increased substantially, the absolute risks of CVT are still small,” the researchers said. “Moreover, withholding oral contraceptives may lead to an increase in unintended pregnancies and thus the number of pregnancy-related thrombosis cases.”
After controlling for multiple variables, CVT was 2.63 times more likely to occur in obese individuals, compared with those of normal weight. When the findings were stratified by sex, a BMI greater than 30 kg/m2 had no significant impact on CVT in men, but the odds rose 3.5-fold in women, the investigators reported online March 14 in JAMA Neurology (JAMA Neurol. 2016 Mar 14. doi: 10.1001/jamaneurol.2016.000100).
On further analysis, overweight and obesity had a dose-dependent impact on the odds of CVT among women who used OCs. Adjusted odds ratios were 11.87 for those with BMIs ranging from 25 kg/m2 to 29 kg/m2, and 29.26 for those with BMIs of 30 kg/m2 or higher when compared against normal-weight women who did not use OCs. No association was found between obesity and CVT risk in women who did not use OCs, the researchers noted.
Patients with CVT were recruited in 2006-2014 from two medical centers, one in the Netherlands and the other in Switzerland. The controls were part of the Dutch Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA) study. Overall, patients with CVT were more likely to be younger than controls (median age 40 years vs. 48 years). They also were more likely than controls to be female (72% vs. 53%), users of oral contraceptives (73% vs. 24%) and have a history of cancer (9% vs. 4%).
The study was limited by several factors, including the small number of CVT cases, the lack of complete BMI data for the study population, and time difference in recruitment of cases and controls, the researchers noted, but they advised clinicians to keep the risk in mind when counseling obese women about OC use.
“Alternative methods of contraception that are not associated with thrombosis, such as an intrauterine device, might be offered to these women,” they wrote.
The study was funded by grants from the Netherlands Organisation for Scientific Research, the Dutch Thrombosis Society, the Remmert Adriaan Laan Foundation, and the Swiss Heart Foundation. Study coauthor Dr. Marcel Arnold disclosed receiving honoraria for giving lectures and serving on advisory boards for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Covidien.
Obese women taking oral contraceptives had a 30-fold increased odds for cerebral venous thrombosis (CVT), compared with normal-weight women, in an unmatched case-control study of 186 CVT cases and 6,134 controls.
The association between a body-mass index of 30 kg/m2 or higher and increased odds of CVT “appears to be fully attributable to a strongly increased risk in women who use oral contraceptives [OCs],” said Dr. Susanna M. Zuurbier of the Academic Medical Centre in Amsterdam, and her colleagues.
“Although the relative risks are increased substantially, the absolute risks of CVT are still small,” the researchers said. “Moreover, withholding oral contraceptives may lead to an increase in unintended pregnancies and thus the number of pregnancy-related thrombosis cases.”
After controlling for multiple variables, CVT was 2.63 times more likely to occur in obese individuals, compared with those of normal weight. When the findings were stratified by sex, a BMI greater than 30 kg/m2 had no significant impact on CVT in men, but the odds rose 3.5-fold in women, the investigators reported online March 14 in JAMA Neurology (JAMA Neurol. 2016 Mar 14. doi: 10.1001/jamaneurol.2016.000100).
On further analysis, overweight and obesity had a dose-dependent impact on the odds of CVT among women who used OCs. Adjusted odds ratios were 11.87 for those with BMIs ranging from 25 kg/m2 to 29 kg/m2, and 29.26 for those with BMIs of 30 kg/m2 or higher when compared against normal-weight women who did not use OCs. No association was found between obesity and CVT risk in women who did not use OCs, the researchers noted.
Patients with CVT were recruited in 2006-2014 from two medical centers, one in the Netherlands and the other in Switzerland. The controls were part of the Dutch Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA) study. Overall, patients with CVT were more likely to be younger than controls (median age 40 years vs. 48 years). They also were more likely than controls to be female (72% vs. 53%), users of oral contraceptives (73% vs. 24%) and have a history of cancer (9% vs. 4%).
The study was limited by several factors, including the small number of CVT cases, the lack of complete BMI data for the study population, and time difference in recruitment of cases and controls, the researchers noted, but they advised clinicians to keep the risk in mind when counseling obese women about OC use.
“Alternative methods of contraception that are not associated with thrombosis, such as an intrauterine device, might be offered to these women,” they wrote.
The study was funded by grants from the Netherlands Organisation for Scientific Research, the Dutch Thrombosis Society, the Remmert Adriaan Laan Foundation, and the Swiss Heart Foundation. Study coauthor Dr. Marcel Arnold disclosed receiving honoraria for giving lectures and serving on advisory boards for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Covidien.
FROM JAMA NEUROLOGY
Key clinical point: Obesity and oral contraceptive use significantly increased the odds for cerebral venous thrombosis in adults.
Major finding: The risk of CVT was 2.63 times more likely among obese women compared to nonobese women, and nearly 30 times more likely in women taking oral contraceptives.
Data source: An unmatched, case-control study of 186 CVT patients and 6,134 healthy controls.
Disclosures: The study was funded by grants from the Netherlands Organisation for Scientific Research, the Dutch Thrombosis Society, the Remmert Adriaan Laan Foundation, and the Swiss Heart Foundation. Study coauthor Dr. Marcel Arnold disclosed receiving honoraria for giving lectures and serving on advisory boards for Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, and Covidien.
